Rice starch-based sponge for use as topical hemostatic agent

© 2019 Trans Tech Publications Ltd, Switzerland. The topical hemostatic agents in surgery are biomaterials that very important for surgeons to stop bleeding in the complicated areas. Currently available hemostatic agents are often expensive, ineffective or raise safety concerns. Synthetic rice starc...

Full description

Saved in:
Bibliographic Details
Main Authors: Sittiporn Punyanitya, Sakdiphon Thiansem, Anirut Raksujarit, Watchara Sontichai, Rungsarit Koonawoot
Format: Book Series
Published: 2019
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071538804&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/66672
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Description
Summary:© 2019 Trans Tech Publications Ltd, Switzerland. The topical hemostatic agents in surgery are biomaterials that very important for surgeons to stop bleeding in the complicated areas. Currently available hemostatic agents are often expensive, ineffective or raise safety concerns. Synthetic rice starch-based sponge was an inexpensive and promising alternative. In this study, we synthesized and characterized a new hemostatic agent from rice starch and investigated their use as a hemostatic material. The rice starch-based sponge having interconnected pore were synthesized via blending of the rice starch and additive of carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), and glycerol in hot water, freezing and drying by vacuum sublimation with enlarged porosity and rapid swelling behavior. Characteristics of the final products were then investigated by Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and scanning electron microscopy (SEM-EDS). In vivo studies using 4 rabbits with liver injury showed rice starch-based sponge blood aggregate formation as well as bulk blood coagulation inhibition. The biocompatibility tests showed that this sponge is safe and effective after follow-up for at least 6 months of animal and clinical trial.